Switching CGRP (r) MoAbs in migraine: what evidence?
WD Wells-Gatnik, P Martelletti - Expert Opinion on Biological …, 2024 - Taylor & Francis
Introduction Approximately 50% of patients that receive a CGRP (r) MoAb for the
preventative treatment of migraine are expected to discontinue therapy. For patients that …
preventative treatment of migraine are expected to discontinue therapy. For patients that …
[HTML][HTML] Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine
Background and Purpose Monoclonal antibodies (mAbs) targeting calcitonin-gene-related
peptide (CGRP) or its receptor (anti-CGRP-R) have been widely administered to patients …
peptide (CGRP) or its receptor (anti-CGRP-R) have been widely administered to patients …
[HTML][HTML] Switching of monoclonal antibodies against the calcitonin gene-related peptide or its receptor in migraine. Results from a Spanish Cohort
J Arzalluz-Luque, MM Vázquez, RL Pérez… - Neurology …, 2024 - Elsevier
Background Switching between calcitonin gene-related peptide (CGRP) and monoclonal
antibodies (mAbs) may be a beneficial strategy after discontinuation. The aim of this study …
antibodies (mAbs) may be a beneficial strategy after discontinuation. The aim of this study …
Response to letter:“Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing …
K Ihara, S Ohtani, N Watanabe… - Journal of the …, 2023 - jns-journal.com
Journal Pre-proof monoclonal antibody monthly to fremanezumab quarterly based on the
patient's preferred dosing schedule” by Suzuki et al. and appreciated the aspects that they …
patient's preferred dosing schedule” by Suzuki et al. and appreciated the aspects that they …
Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule
S Suzuki, K Suzuki, T Shiina, S Kobayashi… - Journal of the …, 2023 - jns-journal.com
We have read with great interest the paper by Ihara et al.[1] entitled “Switching between anti-
calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and …
calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and …
Estudio de cohortes sobre la efectividad y tolerancia al cambio de anticuerpo monoclonal en pacientes con migraña
A Roux Pesqueira - 2024 - uvadoc.uva.es
La migraña es una de las principales causas de discapacidad en las edades activas de la
vida. No es una enfermedad curable, pero es tratable, aunque muchos de los tratamientos …
vida. No es una enfermedad curable, pero es tratable, aunque muchos de los tratamientos …